摘要
目的比较紫杉醇酯质体与传统紫杉醇持续3 h静脉注射治疗晚期非小细胞肺癌的疗效及不良反应。方法 54例晚期非小细胞肺癌患者,18例用传统紫杉醇注射液(对照组)经预处理治疗,36例用紫杉醇酯质体(试验组)治疗,持续静脉注射3 h。结果试验组和对照组的有效率均为39%,疗效相同(P≥0.05),试验组和对照组非混合溶媒所致的不良反应发生率相似(P≥0.05),混合溶媒所致的不良反应,在试验组低于对照组(P≤0.05)。结论紫杉醇酯质体静脉注射治疗非小细胞肺癌,有效率高,不含聚氧乙基代蓖麻油,混合溶媒所致的不良反应少,不良反应可以耐受。
Objective To compare the effects on advanced non-small cell lung cancer （NSCLC）, as and side effects of paclitaxel liposome formula a 3-hour non-stop infusion. Methods Fifty- four advanced NSCLC patients were randomized into two group. The traditional taxol group （con- trol group, n = 18） was administered the premedications which was used routinely for the preven- tion of hypersensitivity reactions. The paclitaxel liposome group （study group, n = 36） received a 3 -hour non-stop infusion. Results The overall response rate of both groups was 39 %. There was no significant difference between the two groups （P≤0.05）. There was no significant difference in roution toxicity between the two groups （P≤0.05）. The toxicity from the mixed solvent of polyethoxylated castor oil and ethanol was significantly lower in the study group than in the control group （P≤0.05）. Conclusion Paclitaxel liposome is effective in the treatment of NSCLC via in- travenous infusion. It does not contain cremophor EL. It has less side effects. Even if there are side effects, they are tolerable
出处
《实用临床医药杂志》
CAS
2012年第17期116-118,共3页
Journal of Clinical Medicine in Practice
